Co-crystal screening of diclofenac

Pharmaceutics

Volumn 3, Issue 3, 2011, Pages 601-614

  Aakeröy, Christer B ^a   Grommet, Angela B ^a   Desper, John ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Co crystals; Crystallography; Diclofenac; Hydrogen bonding; IR spectroscopy

Indexed keywords

DICLOFENAC; DICLOFENAC 2 AMINO 4 CHLORO 6 METHYLPYRIMIDINE; DICLOFENAC 2 AMINO 4,6 DIMETHYLPYRIMIDINE; DICLOFENAC 2 AMINOPYRIMIDINE; UNCLASSIFIED DRUG;

ARTICLE; COCRYSTAL; CRYSTAL; CRYSTAL STRUCTURE; DRUG FORMULATION; DRUG SCREENING; GRINDING; INFRARED SPECTROSCOPY; STRUCTURE ANALYSIS;

EID: 80052986283     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3030601     Document Type: Article

References (20)

1. Childs, S.; Zaworotko, M. The Reemergence of Cocrystals: The Crystal Clear Writing Is on the Wall: Introduction to Virtual Special Issue on Pharmaceutical Cocrystals. Cryst. Growth Des. 2009, 9, 4208-4211.
2. Good, D.; Rodriguez-Hornedo, N. Solubility Advantage of Pharmaceutical Cocrystals. Cryst. Growth Des. 2009, 9, 2252-2264.
3. Schultheiss, N.; Newman, A. Pharmaceutical Cocrystals and Their Physicochemical Properties Cryst. Growth Des. 2009, 9, 2950-2967.
4. Miroshnyk, I.; Mirza, S.; Sandler, N. Pharmaceutical co-crystals-an opportunity for drug product enhancement. Expert Opin. Drug Del. 2009, 6, 333-341.
5. Lemmerer, A.; Bernstein, J. Hydrogen Bonding Patterns of the Co-Crystal Containing the Pharmaceutically Active Ingredient Isoniazid and Terephthalic Acid. J. Chem. Crystallogr. 2011, 41, 991-997.
6. Desiraju, G. Supramolecular synthons in crystal engineering-a new organic synthesis. Angew. Chem. Int. Ed. 1995, 34, 2311-2327.
7. Stuart, M.; Box, K. Chasing Equilibrium: Measuring the Intrinsic Solubility of Weak Acids and Bases. Anal. Chem. 2005, 77, 983-990.
8. Báthori, N.; Lemmerer, A.; Venter, G.; Bourne, S.; Caira, M. Pharmaceutical Co-crystals with Isonicotinamide-Vitamin B3, Clofibric Acid, and Diclofenac-and Two Isonicotinamide Hydrates. Cryst. Growth Des. 2011, 11, 75-87.
9. APEX2 v2.2.0; Bruker AXS: Madison, WI, USA, 2005.
10. SAINT v7.46a; Bruker AXS: Madison, WI, USA, 1997.
11. XPREP Version 2008/2 for Windows; Bruker AXS: Madison WI, USA, 2008.
12. SHELXTL v6.10; Bruker AXS: Madison, WI, USA, 2008.
13. Allen, F. The Cambridge Structural Database: a quarter of a million crystal structures and rising Acta. Crystallogr. B 2002, B58, 380-388.
14. Aakeröy, C.; Salmon, D. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 2005, 7, 439-448.
15. Etter, M.; Adsmond, D. The use of cocrystallization as a method of studying hydrogen bond preferences of 2-aminopyrimidine. J. Chem. Soc. Chem. Commun. 1990, 8, 589-591.
16. Etter, M.; Adsmond, D.; Britton, D. 2-Aminopyrimidine-succinic acid (1/1) cocrystal. Acta Crystallogr. C 1990, C46, 933-934.
17. Etter, M.; Frankenbach, G.; Adsmond, D. Using hydrogen bonds to design acentric organic materials for nonlinear optical users. Mol. Cryst. Liq. Cryst. 1990, 187, 25-39.
18. Desiraju, G.; Parthasarathy, R. The Nature of Halogen-Halogen Interactions: Are Short Halogen Contacts Due to Specific Attractive Forces or Due to Close Packing of Nonspherical Atoms? J. Am. Chem. Soc. 1989, 111, 8725-8726.
19. Aakeröy, S.; Forbes, S.; Desper, J. Using Cocrystals to Systematically Modulate Aqueous Solubility and Melting Behavior of an Anticancer Drug J. Am. Chem. Soc. 2009, 131, 17048-17049.
20. Lynch, D. Private Communication to the Cambridge Structural Database, version 5.32; CCDC: Cambridge, UK, 2009; deposition number CCDC 717577, CCDC 717805, CCDC 717879.